相关实验视频

Updated: Jun 21, 2026

Myocardial Infarction and Functional Outcome Assessment in Pigs

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

在经皮冠状动脉干预治疗慢性全闭塞后,评估左心室功能

Yasser M Sammour¹, Rody G Bou Chaaya¹, Chloe Kharsa¹

¹Department of Cardiology, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas.

Journal of the Society for Cardiovascular Angiography & Interventions

|March 10, 2025

概括

慢性全闭性冠状动脉外皮干预改善左心室喷射率,特别是在基线功能减弱的患者中. 成功的程序显示出显著的LVEF收益,而不成功的程序则没有.

科学领域:

心脏病学心脏病学
干预心脏病学干预心脏病学
心脏外科手术心脏外科手术

背景情况:

穿皮冠状动脉干预 (PCI) 对慢性全闭 (CTO) 对左心室喷射分数 (LVEF) 的影响是有争议的.
了解CTO PCI后的LVEF变化对于患者管理至关重要.

研究的目的:

评估CTO PCI对LVEF的影响.
在成功的CTO PCI后,确定LVEF改善的预测因素.

主要方法:

在2018-2022年期间接受CTO PCI的142名患者的回顾性分析,使用基线和随访LVEF数据.
基于程序成功,基线LVEF和目标船的分层分析.
后勤回归用于确定LVEF改善的预测因素.

主要成果:

成功的CTO PCI (n=121) 导致LVEF从48.2%增加到51.8% (P < .001).
基线LVEF<50%的患者经历了较大的LVEF改善 (32.6%至40.0%,P<.001),其中48%显示≥10%的改善.
不成功的CTO PCI没有改变LVEF (54.6%对55.2%,P = .746).
降低基线LVEF (<50%) 是LVEF改善的强有力的独立预测指标 (aOR,5.60;P <.001).

结论:

成功的CTO PCI与适度的LVEF改善有关.
在基线LVEF降低的患者中,LVEF的增加更为明显.
为了获得LVEF的好处,程序的成功是必不可少的.

关键词:

慢性完全封闭症慢性完全封闭症左前侧下降冠状动脉的左前侧冠状动脉.左侧环动脉的左侧环动脉.左心室喷射分数的部分.左心室的功能是没有的.通过皮肤进行冠状动脉干预.右冠状动脉的右冠状动脉.

更多相关视频

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography

Published on: February 16, 2016

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Primary Outcome Assessment in a Pig Model of Acute Myocardial Infarction

Published on: October 14, 2016

相关概念视频

Cardiac Catheterization III: Left Heart Catheterization

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...

Aortic Regurgitation III: Medical Management

Aortic Regurgitation III: Medical Management

Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...